{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T07:13:36Z","timestamp":1763968416282,"version":"3.37.3"},"reference-count":116,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T00:00:00Z","timestamp":1618790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T00:00:00Z","timestamp":1618790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100007081","name":"Fondation L\u2019Or\u00e9al","doi-asserted-by":"publisher","award":["FY016"],"award-info":[{"award-number":["FY016"]}],"id":[{"id":"10.13039\/501100007081","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Mujeres por Africa Foundation","award":["FY019"],"award-info":[{"award-number":["FY019"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s12094-021-02613-w","type":"journal-article","created":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T08:05:46Z","timestamp":1618819546000},"page":"1979-1994","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Novel combinatorial strategies for boosting the efficacy of immune checkpoint inhibitors in advanced breast cancers"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2559-6299","authenticated-orcid":false,"given":"M. F.","family":"Tolba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Elghazaly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Bousoik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. M. A.","family":"Elmazar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. M.","family":"Tolaney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,19]]},"reference":[{"issue":"6","key":"2613_CR1","doi-asserted-by":"publisher","first-page":"R117","DOI":"10.1186\/bcr3060","volume":"13","author":"E Muraro","year":"2011","unstructured":"Muraro E, Martorelli D, Turchet E, et al. A different immunologic profile characterizes patients with HER-2-overexpressing and HER-2-negative locally advanced breast cancer: implications for immune-based therapies. Breast Cancer Res. 2011;13(6):R117. https:\/\/doi.org\/10.1186\/bcr3060.","journal-title":"Breast Cancer Res"},{"key":"2613_CR2","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3389\/fonc.2017.00156","volume":"7","author":"L Wein","year":"2017","unstructured":"Wein L, Savas P, Luen SJ, et al. Clinical validity and utility of tumor-infiltrating lymphocytes in routine clinical practice for breast cancer patients: current and future directions. Front Oncol. 2017;7:156. https:\/\/doi.org\/10.3389\/fonc.2017.00156.","journal-title":"Front Oncol"},{"issue":"11","key":"2613_CR3","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","volume":"16","author":"AM Goodman","year":"2017","unstructured":"Goodman AM, Kato S, Bazhenova L, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017;16(11):2598\u2013608.","journal-title":"Mol Cancer Ther"},{"key":"2613_CR4","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.breast.2016.07.015","volume":"29","author":"S Luen","year":"2016","unstructured":"Luen S, Virassamy B, Savas P, et al. The genomic landscape of breast cancer and its interaction with host immunity. Breast. 2016;29:241\u201350.","journal-title":"Breast"},{"issue":"9","key":"2613_CR5","doi-asserted-by":"publisher","first-page":"e0163138","DOI":"10.1371\/journal.pone.0163138","volume":"11","author":"V Kotoula","year":"2016","unstructured":"Kotoula V, Lakis S, Vlachos IS, et al. Tumor infiltrating lymphocytes affect the outcome of patients with operable triple-negative breast cancer in combination with mutated amino acid classes. PLoS ONE. 2016;11(9):e0163138.","journal-title":"PLoS ONE"},{"key":"2613_CR6","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.critrevonc.2018.01.005","volume":"122","author":"MF Tolba","year":"2018","unstructured":"Tolba MF, Omar HA. Immunotherapy, an evolving approach for the management of triple negative breast cancer: Converting non-responders to responders. Crit Rev Oncol Hematol. 2018;122:202\u20137. https:\/\/doi.org\/10.1016\/j.critrevonc.2018.01.005.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2613_CR7","doi-asserted-by":"crossref","unstructured":"Dirix LY, Takacs I, al. NPe. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: A phase Ib JAVELIN solid tumor trial. Presented at: 2015 San Antonio Breast Cancer Symposium; San Antonio, TX. Abstract: S1-04. 2015.","DOI":"10.1158\/1538-7445.SABCS15-S1-04"},{"issue":"13 Supplement","key":"2613_CR8","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1158\/1538-7445.am2017-2986","volume":"77","author":"P Schmid","year":"2017","unstructured":"Schmid P, Cruz C, Braiteh FS, et al. Abstract 2986: Atezolizumab in metastatic TNBC (mTNBC): Long-term clinical outcomes and biomarker analyses. Can Res. 2017;77(13 Supplement):2986\u20132986. https:\/\/doi.org\/10.1158\/1538-7445.am2017-2986.","journal-title":"Can Res"},{"key":"2613_CR9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.critrevonc.2019.01.009","volume":"135","author":"HA Omar","year":"2019","unstructured":"Omar HA, Tolba MF. Tackling molecular targets beyond PD-1\/PD-L1: Novel approaches to boost patients\u2019 response to cancer immunotherapy. Crit Rev Oncol Hematol. 2019;135:21\u20139. https:\/\/doi.org\/10.1016\/j.critrevonc.2019.01.009.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"22","key":"2613_CR10","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid P, Adams S, Rugo HS, et al. Atezolizumab and Nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1809615.","journal-title":"N Engl J Med"},{"issue":"2","key":"2613_CR11","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/sj.bjc.6602930","volume":"94","author":"L Arnould","year":"2006","unstructured":"Arnould L, Gelly M, Penault-Llorca F, et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer. 2006;94(2):259\u201367. https:\/\/doi.org\/10.1038\/sj.bjc.6602930.","journal-title":"Br J Cancer"},{"issue":"14","key":"2613_CR12","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","volume":"365","author":"D Slamon","year":"2011","unstructured":"Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273\u201383. https:\/\/doi.org\/10.1056\/NEJMoa0910383.","journal-title":"N Engl J Med"},{"issue":"12","key":"2613_CR13","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1038\/s41416-018-0318-0","volume":"119","author":"T Triulzi","year":"2018","unstructured":"Triulzi T, Regondi V, De Cecco L, et al. Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit. Br J Cancer. 2018;119(12):1487\u201394. https:\/\/doi.org\/10.1038\/s41416-018-0318-0.","journal-title":"Br J Cancer"},{"issue":"17","key":"2613_CR14","doi-asserted-by":"publisher","first-page":"7142","DOI":"10.1073\/pnas.1016569108","volume":"108","author":"J Stagg","year":"2011","unstructured":"Stagg J, Loi S, Divisekera U, et al. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci USA. 2011;108(17):7142\u20137. https:\/\/doi.org\/10.1073\/pnas.1016569108.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"2613_CR15","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1200\/jco.2014.58.1967","volume":"33","author":"C Denkert","year":"2015","unstructured":"Denkert C, von Minckwitz G, Brase JC, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol. 2015;33(9):983\u201391. https:\/\/doi.org\/10.1200\/jco.2014.58.1967.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2613_CR16","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/s1470-2045(18)30812-x","volume":"20","author":"S Loi","year":"2019","unstructured":"Loi S, Giobbie-Hurder A, Gombos A, et al. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b\u20132 trial. Lancet Oncol. 2019;20(3):371\u201382. https:\/\/doi.org\/10.1016\/s1470-2045(18)30812-x.","journal-title":"Lancet Oncol"},{"issue":"5","key":"2613_CR17","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1177\/1758834014539183","volume":"6","author":"PF Peddi","year":"2014","unstructured":"Peddi PF, Hurvitz SA. Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential. Ther Adv Med Oncol. 2014;6(5):202\u20139. https:\/\/doi.org\/10.1177\/1758834014539183.","journal-title":"Ther Adv Med Oncol"},{"key":"2613_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz242","author":"LA Emens","year":"2019","unstructured":"Emens LA, Esteva FJ, Beresford M, et al. 305OOverall survival (OS) in KATE2, a phase II study of programmed death ligand 1 (PD-L1) inhibitor atezolizumab (atezo)+trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+ advanced breast cancer (BC). Ann Oncol. 2019. https:\/\/doi.org\/10.1093\/annonc\/mdz242.","journal-title":"Ann Oncol"},{"key":"2613_CR19","first-page":"1","volume":"1","author":"SJ Keam","year":"2020","unstructured":"Keam SJ. Trastuzumab Deruxtecan: First Approval. Drugs. 2020;1:1\u20138.","journal-title":"Drugs."},{"issue":"4","key":"2613_CR20","doi-asserted-by":"publisher","first-page":"556","DOI":"10.4103\/ijmpo.ijmpo_264_19","volume":"40","author":"M Dhanushkodi","year":"2019","unstructured":"Dhanushkodi M. Trastuzumab deruxtecan: A quantum leap in HER2-positive breast cancer. Indian J Med Paediatr Oncol. 2019;40(4):556\u20138.","journal-title":"Indian J Med Paediatr Oncol"},{"issue":"3","key":"2613_CR21","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1172\/JCI61226","volume":"122","author":"HE Kohrt","year":"2012","unstructured":"Kohrt HE, Houot R, Weiskopf K, et al. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Investig. 2012;122(3):1066\u201375.","journal-title":"J Clin Investig"},{"issue":"5","key":"2613_CR22","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u201374. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013.","journal-title":"Cell"},{"issue":"4","key":"2613_CR23","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1158\/2159-8290.cd-15-0894","volume":"6","author":"CJ Sherr","year":"2016","unstructured":"Sherr CJ, Beach D, Shapiro GI. Targeting CDK4 and CDK6: from discovery to therapy. Cancer Discov. 2016;6(4):353\u201367. https:\/\/doi.org\/10.1158\/2159-8290.cd-15-0894.","journal-title":"Cancer Discov"},{"issue":"1","key":"2613_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/s1470-2045(14)71159-3","volume":"16","author":"RS Finn","year":"2015","unstructured":"Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25\u201335. https:\/\/doi.org\/10.1016\/s1470-2045(14)71159-3.","journal-title":"Lancet Oncol"},{"issue":"17","key":"2613_CR25","doi-asserted-by":"publisher","first-page":"5218","DOI":"10.1158\/1078-0432.ccr-17-0754","volume":"23","author":"MN Dickler","year":"2017","unstructured":"Dickler MN, Tolaney SM, Rugo HS, et al. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR(+)\/HER2(-) Metastatic Breast Cancer. Clin Cancer Res. 2017;23(17):5218\u201324. https:\/\/doi.org\/10.1158\/1078-0432.ccr-17-0754.","journal-title":"Clin Cancer Res"},{"issue":"7668","key":"2613_CR26","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nature23465","volume":"548","author":"S Goel","year":"2017","unstructured":"Goel S, DeCristo MJ, Watt AC, et al. CDK4\/6 inhibition triggers anti-tumour immunity. Nature. 2017;548(7668):471\u20135. https:\/\/doi.org\/10.1038\/nature23465.","journal-title":"Nature"},{"issue":"15","key":"2613_CR27","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1200\/JCO.2020.38.15_suppl.1051","volume":"38","author":"HS Rugo","year":"2020","unstructured":"Rugo HS, Kabos P, Beck JT, et al. A phase Ib study of abemaciclib in combination with pembrolizumab for patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer (MBC) (NCT02779751): Interim results. J Clin Oncol. 2020;38(15):1051\u20131051. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.1051.","journal-title":"J Clin Oncol"},{"issue":"4 Supplement","key":"2613_CR28","doi-asserted-by":"publisher","first-page":"P3","DOI":"10.1158\/1538-7445.sabcs19-p3-11-04","volume":"80","author":"Y Yuan","year":"2020","unstructured":"Yuan Y, Yost SE, Lee JS, et al. Abstract P3\u201311\u201304: A phase II study of pembrolizumab, letrozole and palbociclib in patients with metastatic estrogen receptor positive breast cancer. Cancer Res. 2020;80(4 Supplement):P3. https:\/\/doi.org\/10.1158\/1538-7445.sabcs19-p3-11-04.","journal-title":"Cancer Res"},{"issue":"15_Suppl","key":"2613_CR29","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1200\/JCO.2020.38.15_suppl.1000","volume":"38","author":"J Cortes","year":"2020","unstructured":"Cortes J, Cescon DW, Rugo HS, et al. KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer. J Clin Oncol. 2020;38(15_Suppl):1000\u20131000. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.1000.","journal-title":"J Clin Oncol"},{"issue":"9","key":"2613_CR30","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1910549.","journal-title":"N Engl J Med"},{"key":"2613_CR31","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz394.003","author":"P Schmid","year":"2019","unstructured":"Schmid P, Cort\u00e9s J, Dent R, et al. LBA8_PRKEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC). Ann Oncol. 2019. https:\/\/doi.org\/10.1093\/annonc\/mdz394.003.","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"2613_CR32","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1159\/000489063","volume":"94","author":"R Pedersini","year":"2018","unstructured":"Pedersini R, Vassalli L, Claps M, et al. Eribulin in heavily pretreated metastatic breast cancer patients in the real world: a retrospective study. Oncology. 2018;94(Suppl 1):10\u20135. https:\/\/doi.org\/10.1159\/000489063.","journal-title":"Oncology"},{"issue":"5","key":"2613_CR33","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.21873\/anticanres.12541","volume":"38","author":"W Goto","year":"2018","unstructured":"Goto W, Kashiwagi S, Asano Y, et al. Eribulin promotes antitumor immune responses in patients with locally advanced or metastatic breast cancer. Anticancer Res. 2018;38(5):2929\u201338. https:\/\/doi.org\/10.21873\/anticanres.12541.","journal-title":"Anticancer Res"},{"issue":"13 Supplement","key":"2613_CR34","doi-asserted-by":"publisher","first-page":"4089","DOI":"10.1158\/1538-7445.am2019-4089","volume":"79","author":"T Semba","year":"2019","unstructured":"Semba T, Tabata K, Ozawa Y, et al. Abstract 4089: Antitumor activity of eribulin in combination with anti-PD1 antibody in a mouse syngeneic breast cancer model. Can Res. 2019;79(13 Supplement):4089\u20134089. https:\/\/doi.org\/10.1158\/1538-7445.am2019-4089.","journal-title":"Can Res"},{"issue":"6","key":"2613_CR35","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.21873\/anticanres.14317","volume":"40","author":"S Kashiwagi","year":"2020","unstructured":"Kashiwagi S, Asano Y, Goto W, et al. Validation of systemic and local tumour immune response to eribulin chemotherapy in the treatment of breast cancer. Anticancer Res. 2020;40(6):3345\u201354. https:\/\/doi.org\/10.21873\/anticanres.14317.","journal-title":"Anticancer Res"},{"issue":"15_suppl","key":"2613_CR36","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1200\/JCO.2020.38.15_suppl.1015","volume":"38","author":"SM Tolaney","year":"2020","unstructured":"Tolaney SM, Kalinsky K, Kaklamani VG, et al. A phase Ib\/II study of eribulin (ERI) plus pembrolizumab (PEMBRO) in metastatic triple-negative breast cancer (mTNBC) (ENHANCE 1). J Clin Oncol. 2020;38(15_suppl):1015\u20131015. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.1015.","journal-title":"J Clin Oncol"},{"issue":"7713","key":"2613_CR37","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41586-018-0261-5","volume":"559","author":"A Maya-Mendoza","year":"2018","unstructured":"Maya-Mendoza A, Moudry P, Merchut-Maya JM, et al. High speed of fork progression induces DNA replication stress and genomic instability. Nature. 2018;559(7713):279\u201384.","journal-title":"Nature"},{"issue":"6330","key":"2613_CR38","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1126\/science.aam7344","volume":"355","author":"CJ Lord","year":"2017","unstructured":"Lord CJ, Ashworth A. PARP inhibitors: Synthetic lethality in the clinic. Science. 2017;355(6330):1152\u20138.","journal-title":"Science"},{"issue":"7035","key":"2613_CR39","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917\u201321.","journal-title":"Nature"},{"issue":"7035","key":"2613_CR40","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase. Nature. 2005;434(7035):913\u20137.","journal-title":"Nature"},{"key":"2613_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14728222.2019.1654458","volume":"13","author":"J Przybycinski","year":"2019","unstructured":"Przybycinski J, Nalewajska M, Marchelek-Mysliwiec M, et al. Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers. Expert Opin Ther Targets. 2019;13:1\u201313. https:\/\/doi.org\/10.1080\/14728222.2019.1654458.","journal-title":"Expert Opin Ther Targets"},{"issue":"14","key":"2613_CR42","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.1158\/1078-0432.CCR-16-3215","volume":"23","author":"S Jiao","year":"2017","unstructured":"Jiao S, Xia W, Yamaguchi H, et al. PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin Cancer Res. 2017;23(14):3711\u201320.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2613_CR43","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13045-019-0784-8","volume":"12","author":"A Li","year":"2019","unstructured":"Li A, Yi M, Qin S, et al. Prospects for combining immune checkpoint blockade with PARP inhibition. J Hematol Oncol. 2019;12(1):98. https:\/\/doi.org\/10.1186\/s13045-019-0784-8.","journal-title":"J Hematol Oncol"},{"issue":"13","key":"2613_CR44","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s12916-015-0425-1","volume":"13","author":"L Livraghi","year":"2015","unstructured":"Livraghi L, Garber JE. PARP inhibitors in the management of breast cancer: current data and future prospects. BMC Med. 2015;13(13):188. https:\/\/doi.org\/10.1186\/s12916-015-0425-1.","journal-title":"BMC Med"},{"issue":"7","key":"2613_CR45","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1158\/0008-5472.can-12-1699","volume":"73","author":"KN Stevens","year":"2013","unstructured":"Stevens KN, Vachon CM, Couch FJ. Genetic susceptibility to triple-negative breast cancer. Can Res. 2013;73(7):2025\u201330. https:\/\/doi.org\/10.1158\/0008-5472.can-12-1699.","journal-title":"Can Res"},{"issue":"1","key":"2613_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-9-86","volume":"9","author":"S Young","year":"2009","unstructured":"Young S, Pilarski RT, Donenberg T, et al. The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer. 2009;9(1):1\u20135.","journal-title":"BMC Cancer"},{"issue":"15","key":"2613_CR47","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1200\/JCO.2020.38.15_suppl.1002","volume":"38","author":"NM Tung","year":"2020","unstructured":"Tung NM, Robson ME, Ventz S, et al. TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded). J Clin Oncol. 2020;38(15):1002\u20131002. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.1002.","journal-title":"J Clin Oncol"},{"issue":"13 Supplement","key":"2613_CR48","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1158\/1538-7445.am2019-2709","volume":"79","author":"A Avrutskaya","year":"2019","unstructured":"Avrutskaya A, Tschuch C, Jensen A, et al. Abstract 2709: Modulation of the tumor-infiltrating lymphocyte population by PARP inhibitor talazoparib in combination with anti-PD1 treatment significantly enhances overall survival in a murine BRCA1<sup>-\/-<\/sup> breast cancer model. Can Res. 2019;79(13 Supplement):2709\u20132709. https:\/\/doi.org\/10.1158\/1538-7445.am2019-2709.","journal-title":"Can Res"},{"issue":"2","key":"2613_CR49","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.ccell.2018.01.009","volume":"33","author":"C-W Li","year":"2018","unstructured":"Li C-W, Lim S-O, Chung EM, et al. Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1. Cancer cell. 2018;33(2):187\u2013201.","journal-title":"Cancer cell."},{"issue":"13 Supplement","key":"2613_CR50","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.1158\/1538-7445.am2018-3101","volume":"78","author":"A Avrutskaya","year":"2018","unstructured":"Avrutskaya A, Tschuch C, Durham W, et al. Abstract 3101: Influence of targeted knockout of the BRCA1 gene on the pharmacologic profile of the mouse breast cancer cell line EMT6 in vitro and in vivo. Can Res. 2018;78(13 Supplement):3101\u20133101. https:\/\/doi.org\/10.1158\/1538-7445.am2018-3101.","journal-title":"Can Res"},{"issue":"11","key":"2613_CR51","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1158\/2326-6066.cir-15-0044","volume":"3","author":"T Higuchi","year":"2015","unstructured":"Higuchi T, Flies DB, Marjon NA, et al. CTLA-4 blockade synergizes therapeutically with PARP inhibition in BRCA1-deficient ovarian cancer. Cancer Immunol Res. 2015;3(11):1257\u201368. https:\/\/doi.org\/10.1158\/2326-6066.cir-15-0044.","journal-title":"Cancer Immunol Res"},{"issue":"5","key":"2613_CR52","first-page":"253","volume":"30","author":"S Domchek","year":"2019","unstructured":"Domchek S, Postel-Vinay S, Im S, et al. 1191O Phase II study of olaparib (O) and durvalumab (D)(MEDIOLA): updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC). Ann Oncol. 2019;30(5):253.","journal-title":"Ann Oncol."},{"issue":"8","key":"2613_CR53","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamaoncol.2019.1029","volume":"5","author":"S Vinayak","year":"2019","unstructured":"Vinayak S, Tolaney SM, Schwartzberg L, et al. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer. JAMA Oncol. 2019;5(8):1132\u201340. https:\/\/doi.org\/10.1001\/jamaoncol.2019.1029.","journal-title":"JAMA Oncol"},{"issue":"6","key":"2613_CR54","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.ctrv.2011.12.002","volume":"38","author":"JR Mackey","year":"2012","unstructured":"Mackey JR, Kerbel RS, Gelmon KA, et al. Controlling angiogenesis in breast cancer: a systematic review of anti-angiogenic trials. Cancer Treat Rev. 2012;38(6):673\u201388.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"2613_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10456-009-9160-6","volume":"13","author":"KJ Gotink","year":"2010","unstructured":"Gotink KJ, Verheul HM. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis. 2010;13(1):1\u201314.","journal-title":"Angiogenesis"},{"issue":"5","key":"2613_CR56","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.celrep.2016.12.079","volume":"18","author":"ME Gonzalez","year":"2017","unstructured":"Gonzalez ME, Martin EE, Anwar T, et al. Mesenchymal Stem Cell-Induced DDR2 Mediates Stromal-Breast Cancer Interactions and Metastasis Growth. Cell Rep. 2017;18(5):1215\u201328. https:\/\/doi.org\/10.1016\/j.celrep.2016.12.079.","journal-title":"Cell Rep"},{"issue":"5","key":"2613_CR57","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.21873\/anticanres.11603.PubMedPMID:28476831;eng","volume":"37","author":"S Sasaki","year":"2017","unstructured":"Sasaki S, Ueda M, Iguchi T, et al. DDR2 expression is associated with a high frequency of peritoneal dissemination and poor prognosis in colorectal cancer. Anticancer Res. 2017;37(5):2587\u201391. https:\/\/doi.org\/10.21873\/anticanres.11603.PubMedPMID:28476831;eng.","journal-title":"Anticancer Res"},{"issue":"6","key":"2613_CR58","doi-asserted-by":"publisher","first-page":"22371","DOI":"10.1038\/srep22371","volume":"3","author":"J Kurashige","year":"2016","unstructured":"Kurashige J, Hasegawa T, Niida A, et al. Integrated molecular profiling of human gastric cancer identifies DDR2 as a potential regulator of peritoneal dissemination. Sci Rep. 2016;3(6):22371. https:\/\/doi.org\/10.1038\/srep22371.","journal-title":"Sci Rep"},{"issue":"6","key":"2613_CR59","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nrc1093","volume":"3","author":"G Bergers","year":"2003","unstructured":"Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003;3(6):401\u201310.","journal-title":"Nat Rev Cancer"},{"issue":"19","key":"2613_CR60","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1056\/NEJMra0706596","volume":"358","author":"RS Kerbel","year":"2008","unstructured":"Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;358(19):2039\u201349.","journal-title":"N Engl J Med"},{"issue":"5","key":"2613_CR61","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1200\/JCO.2005.06.081","volume":"23","author":"DJ Hicklin","year":"2005","unstructured":"Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23(5):1011\u201327.","journal-title":"J Clin Oncol"},{"issue":"10","key":"2613_CR62","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/nrd2130","volume":"5","author":"S Wilhelm","year":"2006","unstructured":"Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discovery. 2006;5(10):835\u201344.","journal-title":"Nat Rev Drug Discovery"},{"issue":"9","key":"2613_CR63","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/nrd2380","volume":"6","author":"S Faivre","year":"2007","unstructured":"Faivre S, Demetri G, Sargent W, et al. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discovery. 2007;6(9):734\u201345.","journal-title":"Nat Rev Drug Discovery"},{"issue":"12","key":"2613_CR64","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1158\/1535-7163.mct-11-0264","volume":"10","author":"FM Yakes","year":"2011","unstructured":"Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011;10(12):2298\u2013308. https:\/\/doi.org\/10.1158\/1535-7163.mct-11-0264.","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"2613_CR65","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1158\/2159-8290.cd-16-0778","volume":"7","author":"A Patnaik","year":"2017","unstructured":"Patnaik A, Swanson KD, Csizmadia E, et al. Cabozantinib eradicates advanced murine prostate cancer by activating antitumor innate immunity. Cancer Discov. 2017;7(7):750\u201365. https:\/\/doi.org\/10.1158\/2159-8290.cd-16-0778.","journal-title":"Cancer Discov"},{"issue":"4","key":"2613_CR66","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1200\/jco.2012.45.0494","volume":"31","author":"DC Smith","year":"2013","unstructured":"Smith DC, Smith MR, Sweeney C, et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol. 2013;31(4):412\u20139. https:\/\/doi.org\/10.1200\/jco.2012.45.0494.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2613_CR67","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1634\/theoncologist.2016-0229","volume":"22","author":"SM Tolaney","year":"2017","unstructured":"Tolaney SM, Ziehr DR, Guo H, et al. Phase II and biomarker study of cabozantinib in metastatic triple-negative breast cancer patients. Oncologist. 2017;22(1):25\u201332. https:\/\/doi.org\/10.1634\/theoncologist.2016-0229.","journal-title":"Oncologist"},{"key":"2613_CR68","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.sabcs19-p3-09-10","author":"R Barroso-Sousa","year":"2020","unstructured":"Barroso-Sousa R, Trippa L, Li T, et al. Abstract P3\u201309\u201310: A phase II study of nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer (mTNBC). Cancer Res. 2020. https:\/\/doi.org\/10.1158\/1538-7445.sabcs19-p3-09-10.","journal-title":"Cancer Res"},{"issue":"7","key":"2613_CR69","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1200\/JCO.2019.37.7_suppl.TPS683","volume":"37","author":"SK Pal","year":"2019","unstructured":"Pal SK, Vaishampayan UN, Castellano DE, et al. Phase Ib (COSMIC-021) trial of cabozantinib (C) in urothelial carcinoma (UC) or C in combination with atezolizumab (A) in patients (pts) with UC, castrate resistant prostate cancer (CRPC) or renal cell carcinoma (RCC). J Clin Oncol. 2019;37(7):683. https:\/\/doi.org\/10.1200\/JCO.2019.37.7_suppl.TPS683.","journal-title":"J Clin Oncol"},{"key":"2613_CR70","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/cancers11050681","volume":"11","author":"RV Iyer","year":"2019","unstructured":"Iyer RV, Maguire O, Kim M, et al. Dose-dependent sorafenib-induced immunosuppression is associated with aberrant NFAT activation and expression of PD-1 in T Cells. Cancers. 2019;11:5. https:\/\/doi.org\/10.3390\/cancers11050681.","journal-title":"Cancers."},{"issue":"6","key":"2613_CR71","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1038\/leu.2008.58","volume":"22","author":"W Zhao","year":"2008","unstructured":"Zhao W, Gu YH, Song R, et al. Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation. Leukemia. 2008;22(6):1226\u201333. https:\/\/doi.org\/10.1038\/leu.2008.58.","journal-title":"Leukemia"},{"issue":"1","key":"2613_CR72","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3390\/cancers6010472","volume":"6","author":"N Espagnolle","year":"2014","unstructured":"Espagnolle N, Barron P, Mandron M, et al. Specific Inhibition of the VEGFR-3 Tyrosine Kinase by SAR131675 Reduces Peripheral and Tumor Associated Immunosuppressive Myeloid Cells. Cancers. 2014;6(1):472\u201390. https:\/\/doi.org\/10.3390\/cancers6010472.","journal-title":"Cancers"},{"issue":"1","key":"2613_CR73","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00262-008-0523-4","volume":"58","author":"CM Diaz-Montero","year":"2009","unstructured":"Diaz-Montero CM, Salem ML, Nishimura MI, et al. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer immunology, immunotherapy\u202f: CII. 2009;58(1):49\u201359. https:\/\/doi.org\/10.1007\/s00262-008-0523-4.","journal-title":"Cancer immunology, immunotherapy : CII"},{"issue":"1","key":"2613_CR74","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00432-009-0634-0","volume":"136","author":"CY Liu","year":"2010","unstructured":"Liu CY, Wang YM, Wang CL, et al. Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+\/CD14(-)\/CD15+\/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol. 2010;136(1):35\u201345. https:\/\/doi.org\/10.1007\/s00432-009-0634-0.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"2613_CR75","doi-asserted-by":"publisher","first-page":"794","DOI":"10.4049\/jimmunol.1202088","volume":"190","author":"L Wang","year":"2013","unstructured":"Wang L, Chang EW, Wong SC, et al. Increased myeloid-derived suppressor cells in gastric cancer correlate with cancer stage and plasma S100A8\/A9 proinflammatory proteins. J Immunol. 2013;190(2):794\u2013804. https:\/\/doi.org\/10.4049\/jimmunol.1202088.","journal-title":"J Immunol"},{"issue":"8","key":"2613_CR76","doi-asserted-by":"publisher","first-page":"4499","DOI":"10.4049\/jimmunol.0802740","volume":"182","author":"S Ostrand-Rosenberg","year":"2009","unstructured":"Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol. 2009;182(8):4499\u2013506. https:\/\/doi.org\/10.4049\/jimmunol.0802740.","journal-title":"J Immunol"},{"issue":"8","key":"2613_CR77","doi-asserted-by":"publisher","first-page":"5791","DOI":"10.4049\/jimmunol.181.8.5791","volume":"181","author":"JI Youn","year":"2008","unstructured":"Youn JI, Nagaraj S, Collazo M, et al. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J immunol. 2008;181(8):5791\u2013802. https:\/\/doi.org\/10.4049\/jimmunol.181.8.5791.","journal-title":"J immunol"},{"issue":"6","key":"2613_CR78","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1158\/0008-5472.CAN-11-2684","volume":"72","author":"W Chen","year":"2012","unstructured":"Chen W, Ma T, Shen XN, et al. Macrophage-induced tumor angiogenesis is regulated by the TSC2-mTOR pathway. Cancer Res. 2012;72(6):1363\u201372. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-2684.","journal-title":"Cancer Res"},{"issue":"4","key":"2613_CR79","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1002\/ijc.25113","volume":"127","author":"M van Dongen","year":"2010","unstructured":"van Dongen M, Savage ND, Jordanova ES, et al. Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors. Int J Cancer. 2010;127(4):899\u2013909. https:\/\/doi.org\/10.1002\/ijc.25113.","journal-title":"Int J Cancer"},{"issue":"1","key":"2613_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1476-4598-10-1","volume":"10","author":"H Yang","year":"2011","unstructured":"Yang H, Kim C, Kim M-J, et al. Soluble vascular endothelial growth factor receptor-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder cancer. Mol Cancer. 2011;10(1):1\u201312.","journal-title":"Mol Cancer"},{"issue":"3","key":"2613_CR81","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/S0002-9440(10)64255-1","volume":"161","author":"SF Schoppmann","year":"2002","unstructured":"Schoppmann SF, Birner P, St\u00f6ckl J, et al. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol. 2002;161(3):947\u201356.","journal-title":"Am J Pathol"},{"issue":"13 Supplement","key":"2613_CR82","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1158\/1538-7445.am2017-2634","volume":"77","author":"M Esquerr\u00e9","year":"2017","unstructured":"Esquerr\u00e9 M, Fons P, Badet G, et al. Abstract 2634: EVT801: Standalone cancer immunotherapy in VEGFR3<sup>+<\/sup> tumors and combination with immune checkpoint therapies in VEGFR3<sup>-<\/sup> tumors. Can Res. 2017;77(13 Supplement):2634\u20132634. https:\/\/doi.org\/10.1158\/1538-7445.am2017-2634.","journal-title":"Can Res"},{"issue":"13 Supplement","key":"2613_CR83","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.1158\/1538-7445.am2019-4079","volume":"79","author":"P Fons","year":"2019","unstructured":"Fons P, Esquerre M, Paillasse M, et al. Abstract 4079: EVT801: a selective VEGFR3 inhibitor with the potential for combination with immune-checkpoint therapies, preclinical evidences and plans for first-in-human evaluation. Can Res. 2019;79(13 Supplement):4079\u20134079. https:\/\/doi.org\/10.1158\/1538-7445.am2019-4079.","journal-title":"Can Res"},{"issue":"2","key":"2613_CR84","doi-asserted-by":"publisher","first-page":"eaav2437","DOI":"10.1126\/sciadv.aav2437","volume":"5","author":"MM Tu","year":"2019","unstructured":"Tu MM, Lee FYF, Jones RT, et al. Targeting DDR2 enhances tumor response to anti-PD-1 immunotherapy. Sci Adv. 2019;5(2):eaav2437. https:\/\/doi.org\/10.1126\/sciadv.aav2437.","journal-title":"Sci Adv"},{"issue":"1","key":"2613_CR85","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1097-2765(00)80004-0","volume":"1","author":"A Shrivastava","year":"1997","unstructured":"Shrivastava A, Radziejewski C, Campbell E, et al. An orphan receptor tyrosine kinase family whose members serve as nonintegrin collagen receptors. Mol Cell. 1997;1(1):25\u201334.","journal-title":"Mol Cell"},{"issue":"11","key":"2613_CR86","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1016\/j.celrep.2016.05.033","volume":"15","author":"CA Corsa","year":"2016","unstructured":"Corsa CA, Brenot A, Grither WR, et al. The action of discoidin domain receptor 2 in basal tumor cells and stromal cancer-associated fibroblasts is critical for breast cancer metastasis. Cell Rep. 2016;15(11):2510\u201323. https:\/\/doi.org\/10.1016\/j.celrep.2016.05.033.","journal-title":"Cell Rep"},{"issue":"1\u20133","key":"2613_CR87","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ejphar.2008.10.014","volume":"599","author":"E Day","year":"2008","unstructured":"Day E, Waters B, Spiegel K, et al. Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. Eur J Pharmacol. 2008;599(1\u20133):44\u201353. https:\/\/doi.org\/10.1016\/j.ejphar.2008.10.014.","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"2613_CR88","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1158\/1535-7163.mct-14-0849","volume":"14","author":"L Christiansson","year":"2015","unstructured":"Christiansson L, Soderlund S, Mangsbo S, et al. The tyrosine kinase inhibitors imatinib and dasatinib reduce myeloid suppressor cells and release effector lymphocyte responses. Mol Cancer Ther. 2015;14(5):1181\u201391. https:\/\/doi.org\/10.1158\/1535-7163.mct-14-0849.","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"2613_CR89","doi-asserted-by":"publisher","first-page":"e1253654","DOI":"10.1080\/2162402x.2016.1253654","volume":"6","author":"W Hendrickx","year":"2017","unstructured":"Hendrickx W, Simeone I, Anjum S, et al. Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. Oncoimmunology. 2017;6(2):e1253654. https:\/\/doi.org\/10.1080\/2162402x.2016.1253654.","journal-title":"Oncoimmunology"},{"issue":"6","key":"2613_CR90","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1158\/1078-0432.CCR-15-1125","volume":"22","author":"S Loi","year":"2016","unstructured":"Loi S, Dushyanthen S, Beavis PA, et al. RAS\/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1\/PD-L1 immune checkpoint inhibitors. Clin Cancer Res. 2016;22(6):1499\u2013509.","journal-title":"Clin Cancer Res"},{"issue":"95","key":"2613_CR91","first-page":"275","volume":"17","author":"JM Giltnane","year":"2014","unstructured":"Giltnane JM, Balko JM. Rationale for targeting the Ras\/MAPK pathway in triple-negative breast cancer. Discov Med. 2014;17(95):275\u201383.","journal-title":"Discov Med"},{"key":"2613_CR92","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.sabcs16-p4-22-22","author":"A Brufsky","year":"2017","unstructured":"Brufsky A, Kim S-B, Velu T, et al. Abstract P4\u201322\u201322: Cobimetinib (C) combined with paclitaxel (P) as a first-line treatment in patients (pts) with advanced triple-negative breast cancer (COLET study): Updated clinical and biomarker results. Cancer Res. 2017. https:\/\/doi.org\/10.1158\/1538-7445.sabcs16-p4-22-22.","journal-title":"Cancer Res."},{"issue":"15_suppl","key":"2613_CR93","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1200\/JCO.2019.37.15_suppl.1013","volume":"37","author":"A Brufsky","year":"2019","unstructured":"Brufsky A, Kim S-B, Zvirbule Z, et al. Phase II COLET study: Atezolizumab (A) + cobimetinib (C) + paclitaxel (P)\/nab-paclitaxel (nP) as first-line (1L) treatment (tx) for patients (pts) with locally advanced or metastatic triple-negative breast cancer (mTNBC). J Clin Oncol. 2019;37(15_suppl):1013\u20131013. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.1013.","journal-title":"J Clin Oncol"},{"key":"2613_CR94","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11091318","author":"D Cretella","year":"2019","unstructured":"Cretella D, Digiacomo G, Giovannetti E, et al. PTEN alterations as a potential mechanism for tumor cell escape from PD-1\/PD-L1 Inhibition. Cancers. 2019. https:\/\/doi.org\/10.3390\/cancers11091318.","journal-title":"Cancers."},{"issue":"2","key":"2613_CR95","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1158\/2159-8290.cd-15-0283","volume":"6","author":"W Peng","year":"2016","unstructured":"Peng W, Chen JQ, Liu C, et al. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016;6(2):202\u201316. https:\/\/doi.org\/10.1158\/2159-8290.cd-15-0283.","journal-title":"Cancer Discov"},{"issue":"13 Supplement","key":"2613_CR96","doi-asserted-by":"publisher","first-page":"CT049","DOI":"10.1158\/1538-7445.am2019-ct049","volume":"79","author":"P Schmid","year":"2019","unstructured":"Schmid P, Loirat D, Savas P, et al. Abstract CT049: Phase Ib study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab (atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced\/metastatic triple-negative breast cancer (TNBC). Cancer Res. 2019;79(13 Supplement):CT049. https:\/\/doi.org\/10.1158\/1538-7445.am2019-ct049.","journal-title":"Cancer Res."},{"issue":"3","key":"2613_CR97","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/nri.2016.4","volume":"16","author":"C Cekic","year":"2016","unstructured":"Cekic C, Linden J. Purinergic regulation of the immune system. Nat Rev Immunol. 2016;16(3):177\u201392. https:\/\/doi.org\/10.1038\/nri.2016.4.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"2613_CR98","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1172\/jci45559","volume":"121","author":"L Wang","year":"2011","unstructured":"Wang L, Fan J, Thompson LF, et al. CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice. J Clin Investig. 2011;121(6):2371\u201382. https:\/\/doi.org\/10.1172\/jci45559.","journal-title":"J Clin Investig"},{"issue":"3\u20134","key":"2613_CR99","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/(SICI)1098-2299(199611\/12)39:3\/4<243::AID-DDR3>3.0.CO;2-R","volume":"39","author":"AS Robeva","year":"1996","unstructured":"Robeva AS, Woodard RL, Jin X, et al. Molecular characterization of recombinant human adenosine receptors. Drug Dev Res. 1996;39(3\u20134):243\u201352.","journal-title":"Drug Dev Res"},{"issue":"5","key":"2613_CR100","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1182\/blood-2008-02-136325","volume":"112","author":"SV Novitskiy","year":"2008","unstructured":"Novitskiy SV, Ryzhov S, Zaynagetdinov R, et al. Adenosine receptors in regulation of dendritic cell differentiation and function. Blood. 2008;112(5):1822\u201331.","journal-title":"Blood"},{"issue":"1 Suppl","key":"2613_CR101","doi-asserted-by":"publisher","first-page":"e728","DOI":"10.1111\/j.1365-2567.2009.03075.x","volume":"128","author":"C Linnemann","year":"2009","unstructured":"Linnemann C, Schildberg FA, Schurich A, et al. Adenosine regulates CD8 T-cell priming by inhibition of membrane-proximal T-cell receptor signalling. Immunology. 2009;128(1 Suppl):e728\u201337. https:\/\/doi.org\/10.1111\/j.1365-2567.2009.03075.x.","journal-title":"Immunology"},{"issue":"4","key":"2613_CR102","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/icb.2017.8","volume":"95","author":"D Allard","year":"2017","unstructured":"Allard D, Turcotte M, Stagg J. Targeting A2 adenosine receptors in cancer. Immunol Cell Biol. 2017;95(4):333\u20139. https:\/\/doi.org\/10.1038\/icb.2017.8.","journal-title":"Immunol Cell Biol"},{"key":"2613_CR103","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3389\/fimmu.2016.00109","volume":"7","author":"A Ohta","year":"2016","unstructured":"Ohta A. A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment. Front Immunol. 2016;7:109. https:\/\/doi.org\/10.3389\/fimmu.2016.00109.","journal-title":"Front Immunol"},{"issue":"10","key":"2613_CR104","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1158\/2326-6066.cir-18-0056","volume":"6","author":"SB Willingham","year":"2018","unstructured":"Willingham SB, Ho PY, Hotson A, et al. A2AR antagonism with CPI-444 induces antitumor responses and augments efficacy to anti\u2013PD-(L)1 and Anti\u2013CTLA-4 in preclinical models. Cancer Immunol Res. 2018;6(10):1136\u201349. https:\/\/doi.org\/10.1158\/2326-6066.cir-18-0056.","journal-title":"Cancer Immunol Res"},{"issue":"15_suppl","key":"2613_CR105","doi-asserted-by":"publisher","first-page":"3004","DOI":"10.1200\/JCO.2017.35.15_suppl.3004","volume":"35","author":"L Fong","year":"2017","unstructured":"Fong L, Forde PM, Powderly JD, et al. Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI-444, in anti-PD1\/PDL1 treatment-refractory renal cell (RCC) and non-small cell lung cancer (NSCLC) patients. J Clin Oncol. 2017;35(15_suppl):3004\u20133004. https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.3004.","journal-title":"J Clin Oncol."},{"issue":"6_suppl","key":"2613_CR106","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1200\/JCO.2020.38.6_suppl.129","volume":"38","author":"LC Harshman","year":"2020","unstructured":"Harshman LC, Chu M, George S, et al. Adenosine receptor blockade with ciforadenant +\/- atezolizumab in advanced metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2020;38(6_suppl):129\u2013129. https:\/\/doi.org\/10.1200\/JCO.2020.38.6_suppl.129.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"2613_CR107","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS2646","volume":"37","author":"M Mobasher","year":"2019","unstructured":"Mobasher M, Miller RA, Kwei L, et al. A phase I\/Ib multicenter study to evaluate the humanized anti-CD73 antibody, CPI-006, as a single agent, in combination with CPI-444, and in combination with pembrolizumab in adult patients with advanced cancers. J Clin Oncol. 2019;37(15_suppl):2646. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.TPS2646.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2613_CR108","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.surg.2008.10.010","volume":"145","author":"P Lu","year":"2009","unstructured":"Lu P, Zhu XQ, Xu ZL, et al. Increased infiltration of activated tumor-infiltrating lymphocytes after high intensity focused ultrasound ablation of human breast cancer. Surgery. 2009;145(3):286\u201393. https:\/\/doi.org\/10.1016\/j.surg.2008.10.010.","journal-title":"Surgery"},{"issue":"1","key":"2613_CR109","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ultrasmedbio.2008.08.005","volume":"35","author":"ZL Xu","year":"2009","unstructured":"Xu ZL, Zhu XQ, Lu P, et al. Activation of tumor-infiltrating antigen presenting cells by high intensity focused ultrasound ablation of human breast cancer. Ultrasound Med Biol. 2009;35(1):50\u20137. https:\/\/doi.org\/10.1016\/j.ultrasmedbio.2008.08.005.","journal-title":"Ultrasound Med Biol"},{"key":"2613_CR110","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/978-3-319-22536-4_4","volume-title":"Therapeutic Ultrasound","author":"FM Knuttel","year":"2016","unstructured":"Knuttel FM, van den Bosch MAAJ. Magnetic Resonance-Guided High Intensity Focused Ultrasound Ablation of Breast Cancer. In: Escoffre J-M, Bouakaz A, editors. Therapeutic Ultrasound. Cham: Springer International Publishing; 2016. p. 65\u201381."},{"issue":"13 Supplement","key":"2613_CR111","doi-asserted-by":"publisher","first-page":"4071","DOI":"10.1158\/1538-7445.am2019-4071","volume":"79","author":"S Abe","year":"2019","unstructured":"Abe S, Osada T, Kaneko K, et al. Abstract 4071: A novel combination therapy of high intensity focused ultrasound and PDL1 blockades against advanced breast cancer. Can Res. 2019;79(13 Supplement):4071\u20134071. https:\/\/doi.org\/10.1158\/1538-7445.am2019-4071.","journal-title":"Can Res"},{"issue":"7","key":"2613_CR112","doi-asserted-by":"publisher","first-page":"e0179431","DOI":"10.1371\/journal.pone.0179431","volume":"12","author":"D Charych","year":"2017","unstructured":"Charych D, Khalili S, Dixit V, et al. Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy. PLoS ONE. 2017;12(7):e0179431.","journal-title":"PLoS ONE"},{"key":"2613_CR113","doi-asserted-by":"crossref","unstructured":"Bentebibel S, Hurwitz M, Bernatchez C, et al. A firstin-human study and biomarker analysis of NKTR-214, a novel IL-2-receptor beta\/gamma (\u03b2\u03b3)-biased cytokine, in patients with advanced or metastatic solid tumors. Cancer Disc. 2019.","DOI":"10.1158\/2159-8290.CD-18-1495"},{"key":"2613_CR114","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1200\/JCO.2019.37.15_suppl.2623","volume":"37","author":"ME Hurwitz","year":"2019","unstructured":"Hurwitz ME, Cho DC, Balar AV, et al. Baseline tumor-immune signatures associated with response to bempegaldesleukin (NKTR-214) and nivolumab. J Clin Oncol. 2019;37:2623.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2613_CR115","first-page":"7","volume":"2","author":"S Tolaney","year":"2019","unstructured":"Tolaney S, Baldini C, Spira A, et al. Clinical activity of BEMPEG plus NIVO observed in metastatic TNBC: preliminary results from the TNBC cohort of the Ph1\/2 PIVOT-02 study. Brain. 2019;2(4):7.","journal-title":"Brain"},{"issue":"15_suppl","key":"2613_CR116","doi-asserted-by":"publisher","first-page":"e14040","DOI":"10.1200\/JCO.2017.35.15_suppl.e14040","volume":"35","author":"A Diab","year":"2017","unstructured":"Diab A, Tannir NM, Bernatchez C, et al. A phase 1\/2 study of a novel IL-2 cytokine, NKTR-214, and nivolumab in patients with select locally advanced or metastatic solid tumors. J Clin Oncol. 2017;35(15_suppl):e14040. https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.e14040.","journal-title":"J Clin Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-021-02613-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-021-02613-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-021-02613-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T21:24:55Z","timestamp":1630013095000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-021-02613-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,19]]},"references-count":116,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["2613"],"URL":"https:\/\/doi.org\/10.1007\/s12094-021-02613-w","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"type":"print","value":"1699-048X"},{"type":"electronic","value":"1699-3055"}],"subject":[],"published":{"date-parts":[[2021,4,19]]},"assertion":[{"value":"11 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors approved the final manuscript for submission and publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there is no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study formal consent is not required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}